Heterologous recombinant expression of non-originator NISTmAb

References

• Monoclonal Antibodies - Global Trends in the Competitive, Technological and R&D Landscape. ReportBuyer Ltd, Kent, United Kingdom, October 2017, Report ID: 5174167
   Google Scholar
• Walsh G. 2014. Biopharmaceutical benchmarks 2014. Nature Biotechnol. 32:992–1000. doi:10.1038/nbt.3040.
   PubMed Web of Science ®Google Scholar
• Rathore D, Faustino A, Schiel J, Pang E, Boyne M, Rogstad S. 2018. The role of mass spectrometry in the characterization of biologic protein products. Expert Rev Proteomics. 15:431–449. doi:10.1080/14789450.2018.1469982.
   PubMed Web of Science ®Google Scholar
• Schiel JE, Turner A. 2018. The NISTmAb Reference Material 8671 lifecycle management and quality plan. Anal Bioanal Chem. 410:2067–2078. doi:10.1007/s00216-017-0844-2.
   PubMed Web of Science ®Google Scholar
• Schiel JE, Turner A, Mouchahoir T, Yandrofski K, Telikepalli S, King J, DeRose P, Ripple D, Phinney K. The NISTmAb Reference Material 8671 value assignment, homogeneity, and stability. Anal Bioanal Chem. 2018;410:2127–2139. doi:10.1007/s00216-017-0800-1.
   PubMed Web of Science ®Google Scholar
• Arbogast LW, Brinson RG, Formolo T, Hoopes JT, Marino JP. 2016. 2D 1HN, 15N correlated NMR methods at natural abundance for obtaining structural maps and statistical comparability of monoclonal antibodies. Pharm Res. 33:462–475. doi:10.1007/s11095-015-1802-3.
   PubMed Web of Science ®Google Scholar
• Arbogast LW, Delaglio F, Schiel JE, Marino JP. 2017. Multivariate Analysis of two-dimensional 1H, 13C methyl NMR spectra of monoclonal antibody therapeutics to facilitate assessment of higher order structure. Anal Chem. 89:11839–11845. doi:10.1021/acs.analchem.7b03571.
   PubMed Web of Science ®Google Scholar
• Castellanos MM, Howell SC, Gallagher DT, Curtis JE. 2018. Characterization of the NISTmAb Reference Material using small-angle scattering and molecular simulation: part I: dilute protein solutions. Anal Bioanal Chem. 410:2141–2159. doi:10.1007/s00216-018-0868-2.
   PubMedGoogle Scholar
• Castellanos MM, Mattison K, Krueger S, Curtis JE. 2018. Characterization of the NISTmAb Reference Material using small-angle scattering and molecular simulation: part II: concentrated protein solutions. Anal Bioanal Chem. 410:2161–2171. doi:10.1007/s00216-018-0869-1.
   PubMedGoogle Scholar
• Formolo T, Ly M, Levy M, Kilpatrick L, Lute SC, Phinney K, Marzilli L, Brorson K, Boyne M, Davis D, et al. Determination of the NISTmAb primary structure. In: Schiel JE, Davis DL, Borisov OB, editors. State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization volume 2 biopharmaceutical characterization: the NISTmAb case study. ACS Symposium Series 1201. American Chemical Society; 2015. p. 1–62.
   Google Scholar
• Mouchahoir T, Schiel JE. 2018. Development of an LC-MS/MS peptide mapping protocol for the NISTmAb. Anal Bioanal Chem. 410:2111–2126. doi:10.1007/s00216-018-0848-6.
   PubMed Web of Science ®Google Scholar
• Petersen TN, Brunak S, Von Heijne G, Nielsen H, Signal P. 2011. 4.0: discriminating signal peptides from transmembrane regions. Nat Methods. 8:785–786. doi:10.1038/nmeth.1701.
   PubMed Web of Science ®Google Scholar
• Tarrant RD, Velez-Suberbie ML, Tait AS, Smales CM, Bracewell DG. 2012. Host cell protein adsorption characteristics during protein A chromatography. Biotechnol Prog. 28:1037–1044. doi:10.1002/btpr.1581.
   PubMed Web of Science ®Google Scholar
• Michels DA, Ip AY, Dillon TM, Brorson K, Lute SC, Chavez BK, Prentice KM, Brady LJ, Miller KJ. Separation methods and orthogonal techniques. In: Schiel JE, Davis DL, Borisov OB, editors. State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 2 Biopharmaceutical Characterization: The NISTmAb Case Study. ACS Symposium Series 1201. American Chemical Society; 2015. p. 237–284.
   Google Scholar
• Luo Y, Raso SW, Gallant J, Steinmeyer C, Mabuchi Y, Lu Z, Entrican C, Rouse JC. Evidence for intermolecular domain exchange in the Fab domains of dimer and oligomers of an IgG1 monoclonal antibody. mAbs. 2017;9(6):916–926.
   PubMed Web of Science ®Google Scholar
• Rosenberg AS. 2006. Effects of protein aggregates: an immunologic perspective. AAPS J. 8:E501–7. doi:10.1208/aapsj080359.
   PubMed Web of Science ®Google Scholar
• Turner A, Yandrofski K, Telikepalli S, King J, Heckert A, Filliben J, Ripple D, Schiel JE. Development of orthogonal NISTmAb size heterogeneity control methods. Anal Bioanal Chem. 2018;410(8):2095–2110.
   PubMed Web of Science ®Google Scholar
• Gokarn Y, Agarwal S, Arthur K, Bepperling A, Day ES, Filoti D, Greene DG, Hayes D, Kroe-Barrett R, Laue T, et al. Biophysical techniques for characterizing the higher order structure and interactions of monoclonal antibodies. In: Schiel JE, Davis DL, Borisov OB, editors. State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 2 Biopharmaceutical Characterization: The NISTmAb Case Study. ACS Symposium Series 1201. American Chemical Society; 2015. p. 285–327.
   Google Scholar
• Marino JP, Brinson RG, Hudgens JW, Ladner JE, Gallagher DT, Gallagher ES, Arbogast LW, Huang RYC. Emerging technologies to assess the higher order structure of monoclonal antibodies. In: Schiel JE, Davis DL, Borisov OB, editors. State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 3 Defining the Next Generation of Analytical and Biophysical Techniques. ACS Symposium Series 1202. American Chemical Society; 2015. p. 17–43.
   Google Scholar
• Arbogast LW, Brinson RG, Marino JP. 2015. Mapping monoclonal antibody structure by 2D 13C NMR at natural abundance. Anal Chem. 87:3556–3561. doi:10.1021/ac504804m.
   PubMed Web of Science ®Google Scholar
• Arbogast LW, Brinson RG, Marino JP. 2016. Application of natural isotopic abundance 1H-13C- and 1H-15N-correlated two-dimensional NMR for evaluation of the structure of protein therapeutics. Methods Enzymol. 566:3–34. doi:10.1016/bs.mie.2015.09.037.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay S, Mahajan M, Mehta T, Singh A, Parikh A, Gupta A, Kalita P, Patel M, Mediratta S. Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197. Biosimilars. 2015;5:1–18.
   Google Scholar
• Liu J, Eris T, Li C, Cao S, Kuhns S. 2016. Assessing analytical similarity of proposed amgen biosimilar ABP 501 to Adalimumab. BioDrugs. 30:321–338. doi:10.1007/s40259-016-0184-3.
   PubMed Web of Science ®Google Scholar
• Sandra K, Steenbeke M, Vandenheede I, Vanhoenacker G, Sandra P. 2017. The versatility of heart-cutting and comprehensive two-dimensional liquid chromatography in monoclonal antibody clone selection. J Chromatogr A. 1523:283–292. doi:10.1016/j.chroma.2017.06.052.
   PubMed Web of Science ®Google Scholar
• Kilpatrick EL, Liao WL, Camara JE, Turko IV, Bunk DM. 2012. Expression and characterization of 15N-labeled human C-reactive protein in Escherichia coli and Pichia pastoris for use in isotope-dilution mass spectrometry. Protein Expr Purif. 85:94–99. doi:10.1016/j.pep.2012.06.019.
   PubMed Web of Science ®Google Scholar
• McGivney JBt, Bishop E, Miller K, Casas-Finet J, Yang H, Wei Z, Strouse R, Schenerman M. Evaluation of a synthetic peptide as a replacement for the recombinant fusion protein of respiratory syncytial virus in a potency ELISA. J Pharm Biomed Anal. 2011;54(3):572–576.
   PubMed Web of Science ®Google Scholar
• Gao X, Ji JA, Veeravalli K, Wang YJ, Zhang T, McGreevy W, Zheng K, Kelley RF, Laird MW, Liu J, et al. Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation. J Pharm Sci. 2015;104(2):368–377.
   PubMed Web of Science ®Google Scholar
• Agarabi CD, Schiel JE, Lute SC, Chavez BK, Boyne MT, 2nd, Brorson KA, Khan MA, Read EK. Bioreactor process parameter screening utilizing a Plackett-Burman design for a model monoclonal antibody. J Pharm Sci. 2015;104(6):1919–1928.
   PubMed Web of Science ®Google Scholar
• Sommeregger W, Sissolak B, Kandra K, von Stosch M, Mayer M, Striedner G. Quality by control: Towards model predictive control of mammalian cell culture bioprocesses. Biotechnol J. 2017;12(7):1600546.
   Web of Science ®Google Scholar
• US FDA. Guidance for industry: Scientific considerations in demonstrating biosimilarity to a reference product. Maryland: FDA; 2015.
   Google Scholar
• US FDA. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Maryland: FDA; 2015.
   Google Scholar
• Chow SC, Song F, Bai H. 2017. Sample size requirement in analytical studies for similarity assessment. J Biopharm Stat. 27:233–238. doi:10.1080/10543406.2016.1265545.
   PubMed Web of Science ®Google Scholar